Introduction
Low-grade fibromyxoid sarcoma (LGFMS) is a rare soft tissue tumor that typically affects young to middle-aged adults. 1, 2 A large series of LGFMS cases demonstrated that the median age of onset for this tumor is 34 years (range, 3-78 years). 3 Histologically, LGFMS is composed of bland spindle-shaped cells in a whorled growth pattern, arranged in alternating myxoid and collagenized areas, along with curvilinear capillaries and characteristic arterioles with perivascular fibrosis. Heterotopic ossification and cyst formation have also been reported in these tumors. 4, 5 While LGFMS usually exhibits otherwise benign histologic appearance, a subset of tumors have been reported to show indolent progression, with many cases developing recurrence or metastasis decades later, mainly to the lung. Cytological atypia and tumor necrosis is absent in LGFMS. 6 However, approximately 30% of tumors have focal areas of intermediate-to high-grade sarcoma as shown by hypercellularity, nuclear enlargement, hyperchromatism, necrosis, and high mitotic activity (>5/50 high-powered fields), but the presence of these histologic features is not associated with patient survival. 3, 5 Furthermore, approximately 40% of cases have focal areas of hypocellular collagen cores rimmed by epithelioid fibroblasts, referred to as collagen pseudo-rosettes. Cases of prominent collagen pseudo-rosettes are referred to as hyalinizing spindle cell tumors with giant rosettes. 7 A diagnosis of LGFMS is often difficult by a small biopsy specimen that can lead to a misdiagnosis of malignant tumors as benign or as tumor-like lesions including nodular fasciitis, schwannoma, desmoid-type fibromatosis, neurofibroma, and myxofibrosarcoma. [8] [9] [10] A recent study reported up-regulation of the mucin 4 (MUC4) gene in LGFMS compared to histologically similar tumors and lesions, 10, 11 and MUC4 immunostaining was a sensitive and specific marker of LGFMS in appropriate morphologic context. 2, 7 Several recent studies demonstrated that more than 90% of LGFMS have a balanced chromosomal translocation t(7;16) (q32-34;p11) leading to the fusion of the FUS and CREB3L2 genes, while a minority of cases have a t(11;16) (p11;p11) translocation leading to the fusion of the FUS and CREB3L1 genes. 1, 2, [7] [8] [9] 12 In one report, a small number of LGFMS cases contained EWSR-CREB3L1 gene fusions. 7, 13 http://dx. Here, we report a rare case of LGFMS with central hemorrhagic necrosis in a 77-year-old male patient. Reverse transcription polymerase chain reaction (RT-PCR) from a formalin-fixed, paraffin-embedded (FFPE) biopsy specimen revealed FUS-CREB3L2 gene fusion (exon6/int/exon5), leading to the diagnosis of LGFMS. To the best of our knowledge, this is the second oldest patient to be reported with LGFMS.
Case report
A 77-year-old man was referred to our hospital with a painless mass in the left buttock, which had been gradually growing since he first noticed it 10 years previously. A physical examination revealed an elastic hard mass in the left buttock, and magnetic resonance imaging (MRI) showed a well-demarcated tumor measuring 70 mm in maximum diameter with central hematoma formation. The mass showed low intensity on T1-weighted images (WIs), heterogeneously high intensity on T2-WI ( Fig. 1A and B) , and heterogeneously high signal intensity on fat-suppressed T1-WI ( Fig. 1C and D). Chest and pelvic computed tomography (CT) revealed no evidence of metastatic lesion.
Histopathologically, the tumor was composed of bland spindleshaped cells with a whorled growth pattern on biopsy specimen. The tumor stroma was fibrous, and alternating fibrous and myxoid stroma characteristic of LGFMS were unclear ( Fig. 2A-C) . The tumor showed no nuclear pleomorphism, high cellularity. Focally, tumor cells exhibited wavy appearance. Necrotic area was also observed at the edge of the specimen. Mitosis was not observed. Differential diagnosis on conventional hematoxylin and eosin staining included desmoid-type fibromatosis, schwannoma, and LGFMS. Immunohistochemically, the tumor cells were negative for S-100 protein ( Fig. 2D ) and nuclear staining of ␤-catenin, which are typically present in desmoid-type fibromatosis.
To determine the presence of FUS-CREB3L1 or FUS-CREB3L2 fusion genes in the tumor, we performed RT-PCR on FFPE tumor tissue. Briefly, five 10-m thick paraffin sections were cut from the paraffin-embedded block. RNA was isolated using the RNeasy FFPE kit (QIAGEN, Hilden, Germany), purified, and reverse transcribed to cDNA using the Superscript first-strand synthesis system for RT-PCR (Invitrogen, CA, USA). The primer sequences used for the amplification in this study have been previously described. 14 The PCR product was separated on a 2% agarose gel, and the PCR product of the appropriate size was cut from the gel and sequenced. Sequencing confirmed the presence of a FUS-CREB3L2 fusion gene in this tumor. This gene fusion occurred between the end of exon 6 of FUS and part of exon 5 of CREB3L2 with a 4-bp insertion of unknown origin (Fig. 3A) . Genomic DNA-based long PCR revealed a gene fusion between the part of intron 6 of FUS and part of exon 5 of CREB3L2. The 4-bp sequence at the end of intron 6 was identical to that of a 4-bp insertion of the FUS-CREB3L2 fusion gene, suggesting that the 4-bp insertion was probably derived from the junctional region of the fusion gene (Fig. 3B) . Thus, the fusion gene in this case was exon6/int6/exon5 of the FUS-CREB3L2.
A wide resection of the tumor was performed under a diagnosis of LGFMS. Macroscopically, the resected surface of the surgical specimen was whitish-gray with partial myxoid appearance (Fig. 4A) . Central hemorrhagic necrosis was also observed. Pathological analysis of the resected tumor revealed characteristic alternating fibrous and myxoid stroma with occasional cystic formation (Fig. 4B-D) . Four months after diagnosis, the patient was alive with no evidence of the disease without any adjuvant therapy.
Discussion
LGFMS can occur at any age, but typically affects young to middle-aged adults. 1,2 Two large studies on LGFMS reported that patient age at the time of diagnosis ranges between 6-52 years and 3-78 years, respectively. 3, 5 In the current case, with the long duration of the tumor and cystic changes on MRI, the differential diagnosis on biopsy specimen included ancient/degenerative schwannoma by less atypical spindle shaped cells in the fibrous stroma, because alternating fibrous and myxoid stroma were unclear on the biopsy specimen. Low-grade myxofibrosarcoma (LGMFS) was also an important differential diagnosis considering the age of this patient. Patients with LGMFS are reported to be significantly older than those with LGFMS, and LGMFS more frequently occurs in a superficial location. 6 Furthermore, desmoid-type fibromatosis would clinically and radiolodically be also another important differential diagnosis in this tumor, because cystic changes in desmoid tumors have been reported in a few cases, particularly those arising from the pancreas. [15] [16] [17] Desmoid-type fibromatosis is a locally aggressive infiltrative intra-muscular fibrous tumor, in spite of benign histologic feature. Frequent recurrences can be clinically observed even after wide resection. A "wait-and-see" strategy is, at the present time, preferred in case of asymptomatic or non-progressive disease. Medical treatment such as cyclooxygenase-2 selective inhibitor is another choice for the patients with desmoid-type fibromatosis. 18 As we can see in this case, the importance of molecular pathological diagnosis is clinically increasing, especially in the field of soft tissue sarcomas, because the definite diagnosis made by the molecular pathology such as RT-PCR and specific genetic testing sometimes leads to the application of the tumor specific therapy, 19 although so far there is no specific molecular therapy targeted for the FUS-CREB3L2 or FUS-CREB3L1 gene fusion. In this case, deep location of the tumor and the characteristic histological features of bland spindle cells arranged in a whorled pattern with alternating fibrous and myxoid stroma on the surgically resected tumor confirmed the diagnosis of LGFMS. To the best of our knowledge, the current patient at 77 years of age appears to the second elderly patient diagnosed with LGFMS. Recently, LGFMS was shown to be associated with gene fusions involving CREB3-family genes, which encode members of the basic leucine zipper family of transcription factors. 20 The majority of LGFMS cases (95%) have a fusion of the FUS-CREB3L2, and a minority of cases (5%) have a FUS-CREB3L1 gene fusion. In addition, a small number of cases have EWSR-CREB3L1 gene fusions. 7 The present case harbored an exon6/exon5 type FUS-CREB3L2 fusion gene. Although a 4-bp insertion of unknown origin was observed at the junctional region, genome sequencing of the fusion gene revealed that this 4-bp insertion was likely derived from intron 6 at the junctional region.
Approximately 30% of LGFMS have focal areas of intermediateto high-grade sarcoma, which is inconsistent with a definition of low-grade sarcoma, 3 and tumor necrosis is described to be rare or absent in LGFMS. 3, 5, 6 In this case, hypercellularity, increased mitotic activity, and nuclear enlargement were seldom observed throughout the lesion; however, central hemorrhagic necrosis was observed. This is probably due to the long-time duration of the tumor and the physical compression of the tumor.
In summary, we report a rare case of LGFMS with central hemorrhagic necrosis in a 77-year-old man. To the best of our knowledge, this is the second elderly patient to be diagnosed with LGFMS. Although the patient was disease-free at 4 months after surgery, further long-term follow up is needed.
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